Status:
SUSPENDED
A Two Part Study of Peroral Insulin in Type 2 Diabetes
Lead Sponsor:
Bows Pharmaceuticals AG
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
Insulin is normally not bioavailable when taken through the oral route, as degradation of the molecule may occur both in the ventricle and in the intestine. Oral administration with uptake from the le...
Eligibility Criteria
Inclusion
- Male and female subjects with Type 2 diabetes who were diagnosed for a minimum of 6 months, age 30-65 years.
- Subjects on a stable dose of metformin for at least two months with a total daily dose of
- ≤ 2600 mg/day.
- Subjects demonstrating an insulin resistance value (IR) lower than 3 based on the HOMA-2 model (University of Oxford, 2004) at Screening 2.
- Hemoglobin A1c \<9%.
- Fasting capillary blood glucose within the range 6.0-9.0 mmol/L (108-162 mg/dL) at Screening 1, Screening 2 and Randomization visit. For study Part 1 only, the maximum and minimum of these three measurements may not differ by more than 2 mmol/L.
- Body Mass Index (BMI) of 25-32 kg/m2
- Medically stable as determined by history and physical examination, including vital signs.
- Screening laboratory tests must be within normal range or judged as not clinically significant by Principal investigator/Subinvestigator.
- Negative urine ketoacidosis test
- ECG including QTcB shows no clinically significant abnormality or acute ischemia
- Supine BP ≤ 160/100 mm Hg diastolic/systolic.
- Able to adhere to the study visit schedule, and to understand and comply with other protocol requirements.
- Capable of giving informed consent, which must be obtained prior to any screening procedures.
- Non user of tobacco products for a minimum of 6 months prior to the first dose.
- Negative urine screen for drugs of abuse and an alcohol breath test at screening and check in.
- Negative laboratory screen for Hepatitis B (HBsAg and anti-HBc antibodies), Hepatitis C (anti HCV) and HIV (1\&2).
- Not on any prohibited medication, including alcohol.
- Female subjects willing to use adequate method of contraception from the time of the first dose until one month after the last dose.
- Willing to eat standard meal in accordance with the protocol.
Exclusion
- History of significant coronary disease or renal failure
- Other significant medical problems that would preclude participation in a clinical trial
- Participation in a clinical trial within the prior 3 months
- History of GI surgery or known GI motility disorders.
- History of a serious infection, including but not limited to hepatitis, pneumonia, or pyelonephritis, or have been hospitalized or received intravenous antibiotics for an infection, during the previous two months.
- A chronic or recurrent infectious disease, including but not limited to, chronic renal infection, chronic chest infection (bronchiectasis), sinusitis, recurrent urinary tract infection (recurrent pyelonephritis or chronic nonremitting cystitis), open skin wound, or ulcer.
- Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine (other than diabetes), pulmonary, cardiac, neurologic, or cerebral disease, or any other condition which increases risk of participation in this trial in the opinion of the investigator.
- Currently known malignancy or a history of malignancy within the previous 5 years.
- History of polyps in the gastrointestinal tract.
- Known to have had a substance abuse (drug or alcohol) problem within the previous 5 years
- Unable to undergo venipunctures for study purposes because of poor tolerability or lack of easy access.
- Engaging in any strenuous exercise (such as running or weight lifting or playing any team sports such as soccer for 48 hours prior to admission to the inpatient unit and no strenuous exercise will be permitted for the duration of the study (applies to both part 1 and part 2).
- Donation or loss of 400 ml blood or more within 3 months prior to the first dose or donation of plasma within 7 days prior to the first dose.
- Difficulty in swallowing capsules.
- A recent adult history of clinically significant allergic reaction to any drug.
- Any other medical condition that, in the opinion of the investigator, disqualifies the subject.
- Female subject with positive pregnancy test at screening, Day -1.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00990444
Start Date
September 1 2009
End Date
December 1 2010
Last Update
October 5 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska Trial Alliance, Phase I Unit
Stockholm, Solna, Stockholm, Sweden, 17176